Material is limited
Small biopsies, aspirates, effusions and rare circulating cells may not provide enough viable tumor material for multiple conventional assays.
Minimal-cell response intelligence
Functional evidence from samples too scarce to waste.
VitraCell is developing an investigational platform to measure early, drug-induced biophysical changes in small numbers of viable tumor cells—while preserving the cells for downstream molecular characterization.
Research and development stage. Performance has not been clinically validated. Not intended for diagnosis or treatment selection.
Development thesis
Scarce viable sample→Early functional signal
Measured cell→Molecular identity
Lead applicationViable CTC isolation
Platform extensionMinimal-cell response
Current stagePreclinical development
Partner modelFit-for-purpose pilots
The customer problem
When the sample is irreplaceable, every test becomes a tradeoff.
Pharma translational teams can receive too few viable patient-derived tumor cells to support functional testing, molecular profiling and confirmation from the same specimen.
Expansion changes the equation
Culture or organoid workflows can add time, fail to establish or alter the cellular population the sponsor intended to study.
Function and identity become separated
The sponsor may learn what mutations are present or whether a population survives, but not which measured living cells responded and what those cells were.
The platform thesis
Measure first. Preserve the cell. Confirm its identity.
VitraCell is being designed as a non-destructive measurement workflow for scarce viable samples. The intended value is not another cell count. It is a traceable connection between a living-cell response and the identity of the cell that produced it.
MeasureBiophysical change after controlled drug exposure
ResolveResponse heterogeneity across individual viable cells
RecoverThe measured cells for downstream characterization
Target outputA functional response record linked to cell identity
The evidence program
One platform. Two disciplined development stages.
CTCs remain VitraCell's lead clinical application. Controlled, more abundant cell models provide a capital-efficient path to test the functional-response thesis without pretending the clinical assay already exists.
Current focusCTC foundation
Establish the viable rare-cell engine
Build the repeatable isolation and characterization foundation required before functional testing of rare patient-derived cells is credible.
- Label-free recovery of viable circulating tumor cells
- Recovery, background-cell depletion and post-processing viability
- Repeatable biophysical characterization
- Traceable linkage to downstream cell identity
Next evidence stageFunctional response
Prove that the signal answers a real sponsor question
Use controlled systems to determine whether the platform detects a reproducible treatment-induced change before moving into scarce clinical material.
- Drug-induced change in controlled cancer models
- Known sensitive and resistant comparators
- Minimum-cell-input and repeatability studies
- Comparison with accepted viability or apoptosis assays
Design-partner program
Get involved early enough to shape the pilot—not early enough to inherit the science risk blindly.
VitraCell is seeking pharmaceutical and biotechnology teams with a defined scarce-sample problem. The objective is to co-develop fit-for-purpose requirements within a standardized VitraCell measurement core.
Define the decision
Start with the sponsor's actual development question, sample constraint and required evidence—not a generic technology demonstration.
Set the requirements
Agree on models, compounds, controls, exposure conditions, molecular markers and acceptance criteria before work begins.
Clear the technical gate
Establish repeatability and the relevant response signal in controlled material before advancing to scarce patient-derived samples.
Run a bounded pilot
Execute a defined feasibility study with a research report, transparent limitations and a clear go-or-stop decision.
Best initial fit
Teams that own the compound and the biological question.
Early pharma and biotech partners can define the development decision. CRO participation becomes most valuable as the assay is standardized and ready for transfer or scale.
- Translational medicine teams
- Clinical biomarker groups
- Early clinical development programs
- Precision medicine and companion-diagnostic teams
Built through collaboration
Scientific depth, a clinical feasibility pathway and commercial discipline.
VitraCell's viable-CTC development program is supported by academic engineering and clinical-oncology relationships in South Carolina. Those relationships support the present feasibility pathway; sponsor-specific functional pilots will require their own defined scope, approvals and agreements.
The company
Founder-led, evidence-driven and built in South Carolina.
VitraCell was founded by Gregory Moore to address a practical gap in precision oncology: molecular data can identify a possible target, but it does not directly show how a living tumor-cell population responds.
The company is developing MIPS-5 as a platform for viable rare-cell isolation and, ultimately, minimal-cell functional-response research. Every broader claim remains gated by evidence.
Gregory MooreFounder and CEO
A defined problem—not a generic collaboration